Isthmus Partners, LLC Ligand Pharmaceuticals Inc Transaction History

Isthmus Partners, LLC

  • $815 Million
  • Q3 2024

A detailed history of Isthmus Partners, LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Isthmus Partners, LLC holds 38,554 shares of LGND stock, worth $4.73 Million. This represents 0.47% of its overall portfolio holdings.

Number of Shares
38,554
Previous 48,176 19.97%
Holding current value
$4.73 Million
Previous $4.06 Million 4.88%
% of portfolio
0.47%
Previous 0.49%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$82.7 - $110.11 $795,739 - $1.06 Million
-9,622 Reduced 19.97%
38,554 $3.86 Million
Q2 2024

Aug 06, 2024
SELL
$68.53 - $87.91 $10,622 - $13,626
-155 Reduced 0.32%
48,176 $4.06 Million
Q1 2024

May 07, 2024
BUY
$68.64 - $89.2 $959,861 - $1.25 Million
13,984 Added 40.71%
48,331 $3.53 Million
Q4 2023

Feb 12, 2024
BUY
$49.57 - $72.63 $75,842 - $111,123
1,530 Added 4.66%
34,347 $2.45 Million
Q3 2023

Nov 14, 2023
BUY
$58.86 - $72.67 $472,410 - $583,249
8,026 Added 32.37%
32,817 $1.97 Million
Q2 2023

Aug 03, 2023
SELL
$69.53 - $79.33 $7,161 - $8,170
-103 Reduced 0.41%
24,791 $1.79 Million
Q1 2023

May 10, 2023
BUY
$65.67 - $77.08 $332,552 - $390,333
5,064 Added 25.54%
24,894 $1.83 Million
Q4 2022

Feb 10, 2023
SELL
$61.72 - $96.74 $3,641 - $5,707
-59 Reduced 0.3%
19,830 $1.32 Million
Q3 2022

Nov 14, 2022
BUY
$0.01 - $107.56 $42 - $452,720
4,209 Added 26.84%
19,889 $1.71 Million
Q2 2022

Aug 08, 2022
BUY
$74.52 - $117.06 $71,539 - $112,377
960 Added 6.52%
15,680 $1.4 Million
Q1 2022

May 04, 2022
BUY
$94.99 - $151.56 $102,589 - $163,684
1,080 Added 7.92%
14,720 $1.66 Million
Q4 2021

Jan 25, 2022
BUY
$127.69 - $165.85 $16,982 - $22,058
133 Added 0.98%
13,640 $2.11 Million
Q3 2021

Nov 10, 2021
BUY
$102.33 - $144.73 $5,935 - $8,394
58 Added 0.43%
13,507 $1.88 Million
Q2 2021

Aug 10, 2021
BUY
$113.03 - $155.64 $35,378 - $48,715
313 Added 2.38%
13,449 $1.76 Million
Q1 2021

May 17, 2021
SELL
$99.52 - $215.83 $28,164 - $61,079
-283 Reduced 2.11%
13,136 $2 Million
Q4 2020

Feb 16, 2021
BUY
$80.55 - $106.05 $115,589 - $152,181
1,435 Added 11.97%
13,419 $1.34 Million
Q3 2020

Nov 04, 2020
BUY
$89.56 - $126.72 $94,217 - $133,309
1,052 Added 9.62%
11,984 $1.14 Million
Q2 2020

Aug 10, 2020
BUY
$68.28 - $123.65 $9,081 - $16,445
133 Added 1.23%
10,932 $1.22 Million
Q1 2020

May 15, 2020
SELL
$63.37 - $107.88 $41,127 - $70,014
-649 Reduced 5.67%
10,799 $785,000
Q4 2019

Feb 07, 2020
BUY
$96.94 - $113.59 $8,821 - $10,336
91 Added 0.8%
11,448 $1.19 Million
Q3 2019

Nov 14, 2019
BUY
$86.25 - $120.16 $136,361 - $189,972
1,581 Added 16.17%
11,357 $1.13 Million
Q2 2019

Aug 09, 2019
BUY
$107.38 - $129.34 $1.05 Million - $1.26 Million
9,776 New
9,776 $1.12 Million
Q1 2019

Apr 19, 2019
SELL
$105.93 - $142.47 $730,599 - $982,615
-6,897 Closed
0 $0
Q4 2018

Feb 04, 2019
BUY
$128.36 - $272.13 $93,061 - $197,294
725 Added 11.75%
6,897 $936,000
Q3 2018

Nov 14, 2018
SELL
$211.18 - $274.49 $100,521 - $130,657
-476 Reduced 7.16%
6,172 $1.69 Million
Q2 2018

Aug 02, 2018
SELL
$150.77 - $207.98 $18,997 - $26,205
-126 Reduced 1.86%
6,648 $1.38 Million
Q1 2018

May 11, 2018
SELL
$138.63 - $182.62 $14,278 - $18,809
-103 Reduced 1.5%
6,774 $1.12 Million
Q4 2017

Feb 05, 2018
SELL
$128.36 - $147.04 $2,695 - $3,087
-21 Reduced 0.3%
6,877 $942,000
Q3 2017

Nov 02, 2017
BUY
$120.91 - $137.94 $834,037 - $951,510
6,898
6,898 $939,000

Others Institutions Holding LGND

# of Institutions
257
Shares Held
18.2M
Call Options Held
26.8K
Put Options Held
9.3K
View Full List

About LIGAND PHARMACEUTICALS INC

LGND Quotes by TradingView
  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $2.07B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Isthmus Partners, LLC Portfolio

Follow Isthmus Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Isthmus Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Isthmus Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email